Market Overview

Analysis: The Market Has Oversold Shares Of Sabra Health Care REIT With A Catalyst On The Horizon

Analysis: The Market Has Oversold Shares Of Sabra Health Care REIT With A Catalyst On The Horizon

With Sabra Health Care REIT Inc (NASDAQ: SBRA) down 16.6 percent since it announced its purchase of Care Capital Properties Inc in May, JMP Securities sees a buying opportunity.

Analyst Peter Martin upgraded the stock Tuesday expecting a catalyst in Sabra’s upcoming investor call and pro-forma guidance as well as a 9-percent yield from its merger with Care Capital.

The anticipated deal gains align with expectations from Egan-Jones and Glass Lewis, which in August urged investors to vote in approval in spite of opposing assessments. Eminence Capital and Hudson Bay Capital had earlier rejected the proposition, with the latter asserting that the $7.4 billion transaction “could prove fatally expensive” to shareholders.

“Based on this drastic decline in Sabra shareholder value, it is clear to us that the strategic rationale of the CCP Acquisition, as stated by Sabra management, has not been accepted by the market and the CCP Acquisition is not in the best interests of shareholders,” Hudson Bay wrote in a July open letter.

At its post-announcement nadir, Sabra had traded down 22.4 percent.

Mizuho Securities corroborated negative sentiments with a downgrade to Sell ━ notably, Sabra’s only such rating. The Street now has four Buys and three Holds on the stock, with recent upgrades from both Jefferies and JMP.

Martin maintains a $23 price target on the stock, foreseeing a 10-percent premium in net asset value representing discounts of 8-percent and 16-percent to industry peers Omega Healthcare Investors Inc (NYSE: OHI) and CareTrust REIT Inc (NASDAQ: CTRE).

At the time of publication, Sabra was trading at $22.43.

Related BZPro Headline: Shareholders of Sabra and Care Capital Properties, Respectively, Approve Merger

Latest Ratings for SBRA

Mar 2020Wells FargoMaintainsEqual-Weight
Feb 2020MizuhoUpgradesNeutralBuy
Feb 2020BarclaysMaintainsOverweight

View More Analyst Ratings for SBRA
View the Latest Analyst Ratings


Related Articles (SBRA)

View Comments and Join the Discussion!

Posted-In: JMP SecuritiesAnalyst Color REIT Upgrades Health Care Analyst Ratings General Real Estate

Latest Ratings

BBCanaccord GenuityMaintains6.0
ATROCanaccord GenuityMaintains14.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at